Home Blog Page 2029

Netcore Cloud Achieves CMMI Level 3 Appraisal

By
Advertorial Desk
-

MUMBAI, India, Oct. 29, 2025 /PRNewswire/ — Netcore Cloud, a global leader in AI-powered customer engagement and personalisation, today announced that it has been appraised at level 3 of ISACA’s Capability Maturity Model Integration (CMMI®). The appraisal was performed by Equalitas Certifications Limited.

CMMI is a proven, outcome-based performance model and the globally accepted standard for improving capability, optimizing business performance and aligning operations to business goals.

An appraisal at Maturity Level 3 indicates the organization is performing at a ‘defined’ level. At this level, processes are well characterized and understood, and are described in standards, procedures, tools and methods. The organization’s set of standard processes, which is the basis for Maturity Level 3, is established and improved over time.

“Organizations worldwide are harnessing CMMI to elevate their business performance to new heights, creating a sustainable competitive advantage in the process,” says Ron Lear, VP, Frameworks and Models at ISACA. “We commend Netcore Cloud on achieving this CMMI appraisal level and demonstrating their ability as a high-performing organization.”

“Achieving this CMMI appraisal is more than just a certification; it’s a reflection of our relentless pursuit of perfection and our deep commitment to our customers,” said Kuldeep Sengar, Group CTO of Netcore Cloud. “This milestone assures our clients that their trust in us is well-placed and validates our eligibility to engage with top-tier clients worldwide.”

This achievement builds on the company’s existing compliance with global standards and complements Netcore Cloud’s robust data sensitivity benchmarks, assuring customers that their information is handled with the utmost care and security. By integrating best practices from CMMI with its existing quality and security frameworks, Netcore Cloud is equipped to expand its business into new, highly regulated markets and demonstrate an elite level of operational maturity.

For more information about Netcore Cloud’s CMMI appraisal and its commitment to quality, please visit https://netcorecloud.com/

About Netcore Cloud

Netcore Cloud, a global leader in marketing technology, empowers marketers with its comprehensive Customer Engagement and Experience Suite to create personalized, omnichannel experiences. Leveraging AI to integrate customer data, Netcore enables targeted segments and meaningful digital interactions. Trusted by over 6,500 brands across sectors like Ecommerce, Retail, Banking and Financial Services, Media and Entertainment, and Travel, its marquee clients include Walmart, Unilever, Tommy Hilfiger, Domino’s, McDonald’s, Pizza Hut, and Crocs. For more information, visit netcorecloud.com

Logo: https://laotiantimes.com/wp-content/uploads/2025/10/netcore_logo.jpg

 

Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University

By
Advertorial Desk
-

TOKYO, Oct. 29, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.73 billion (USD 11.6 million1) in four R&D projects for the development of diagnostics and a vaccine for tuberculosis (TB), neglected tropical diseases (NTDs), and malaria.2 

Investment of JPY 390 Million (USD 2.6 million1) to Advance a Novel Rapid Diagnostic for Tuberculosis
Tuberculosis (TB) remains one of the world’s most devastating infectious diseases, affecting over 10 million people and causing 1.3 million deaths annually.3 In resource-limited settings, over 3 million people go undiagnosed each year due to the lack of suitable, accessible diagnostic tools4—particularly at the point of first contact with the healthcare system. Severely ill patients and children, who often struggle to produce sputum, are especially at risk of being missed by routine diagnostics. To help address this gap, the GHIT Fund is investing JPY 390 million (USD 2.6 million1) in a global partnership aimed at assessing and introducing an innovative TB diagnostic. This project is being led by the United Nations Office for Project Services (UNOPS) hosted organization Stop TB Partnership, in collaboration with FUJIFILM Corporation, the Liverpool School of Tropical Medicine, and research institutions in Cameroon, Nigeria, and Germany. The investment builds on a prior GHIT-supported project that received approximately JPY 600 million (USD 4.0 million1) between 2016 and 2023 and seeks to bring a highly sensitive urine-based rapid test progressing toward implementation.

The project will evaluate the performance and feasibility of FUJIFILM SILVAMP TB LAM II, a rapid test developed by Fujifilm to detect urinary LAM antigens, along with a urine concentration device (UCD). This innovative diagnostic approach eliminates the need for sputum collection and has the potential to significantly improve diagnostic accuracy for a broad range of people—including those living with or without HIV, severely ill individuals, and children. By enabling earlier and more accessible diagnosis, particularly in underserved settings, this project aims to reduce diagnostic delays and disparities, help limit the spread of TB, and ultimately support global efforts to end the disease.

JPY 681 million (USD 4.5 million1) Investment in a Phase I Clinical Study of a Leishmaniasis Vaccine
Leishmaniasis is a parasitic disease transmitted by sandflies and is recognized by the World Health Organization (WHO) as an NTD. The GHIT Fund will invest JPY 681 million (USD 4.5 million1) in Phase I clinical trials of this promising vaccine, in a project jointly conducted by the Ohio State University and Nagasaki University. The project will evaluate the safety and immunogenicity of the investigational vaccine in healthy adults living in endemic regions of Brazil and Kenya. In addition, on July 25, 2025, the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug Application (IND) to initiate human clinical trials. This milestone represents a significant step forward in the fight against leishmaniasis and will accelerate product development and early access.

In addition, the GHIT Fund will invest a total of approximately JPY 666 million (USD 4.4 million1) in the following two R&D projects:
(1) Product development project for new rapid diagnostic test for strongyloidiasis by Drugs & Diagnostics for Tropical Diseases (DDTD), Medical & Biological Laboratories Co., Ltd. (MBL), IRCCS Sacro Cuore Don Calabria Hospital, QIMR Berghofer Medical Research Institute, Fundacion Mundo Sano, and Big Eye Diagnostics, Inc. (BEDx) 
(2) Target research project for malaria diagnostics by Ehime University, Institute of Tropical Medicine (NEKKEN) Nagasaki University, and Universiti Malaysia Sabah

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages. The four projects funded in this round bring together partners from a total of 11 countries. Since its inception, the GHIT Fund has worked with more than 190 research and development partners, including more than 130 overseas institutions. The GHIT Fund serves as a bridge connecting pharmaceutical companies, universities, and research institutes in Japan with their counterparts around the world.

As of September 30, 2025, the GHIT Fund has invested in 42 projects, including 17 discovery projects, 14 preclinical projects, and 11 clinical trials.6 The total amount of investments since 2013 is JPY 41.0 billion (USD 275 million1) (Appendix 2).

1 USD1 = JPY148.81, the approximate exchange rate on September 30, 2025.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002, RFP2024-001, and RFP2025-001 for the Product Development Platform and the Target Research Platform, which were open for applications from June 2023 to July 2025.
3 WHO: https://www.who.int/news-room/fact-sheets/detail/tuberculosis 
4 Stop TB Partnership https://www.stoptb.org/missing-tb-millions 
5 WHO: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis 
6 This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en

Appendix 1. Project Details 

ID: G2023-212

Project Title

Multi-site field trial of the FUJIFILM SILVAMP TB LAM Ⅱ including the diagnostic accuracy of a urine concentration device

Collaboration

Partners

1. Stop TB Partnership (Switzerland)

2. FUJIFILM Corporation (Japan)

3. Liverpool School of Tropical Medicine (LSTM) (UK)

4. Center for Health Promotion and Research (CHPR) (Cameroon)

5. Friends for International TB Relief (FIT) (Germany)

6. Zankli Research Centre, Bingham University Nigeria (ZRC) (Nigeria)

Disease

Tuberculosis

Intervention

Diagnostics

Stage

Product Validation

Awarded Amount

JPY 390,000,000 (USD 2.6 million)

Status

Continued project

Summary

[Project objective]

The primary objective of the project is to provide evidence on the performance of Fujifilm’s redesigned SILVAMP TB LAM II assay as well as a urine concentration device (UCD) which is expected to further increase sensitivity especially in HIV-negative individuals to obtain a WHO policy recommendation with strengthened evidence based on the operationalization, costing and feasibility studies to be conducted on this project.

[Project design]

The project team will prospectively evaluate the performance of the SILVAMP TB LAM Ⅱ assay as well as a urine concentration device across multiple sites in Cameroon, Nigeria and Vietnam. The project team will evaluate test performance among PLHIV and HIV-negative adults as well as children irrespective of HIV co-infection. Operationalization, costing and feasibility of the assay will also be addressed.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/246/en

ID: G2024-101

Project Title

Evaluation of the Safety and Immunogenicity of the cGMP LmCen-/- Vaccine in Phase I Clinical Trials

Collaboration

Partners

1. The Ohio State University (USA)

2. Nagasaki University (Japan)

Disease

Leishmaniasis

Intervention

Vaccines

Stage

Clinical Phase I

Awarded Amount

JPY 681,063,113 (USD 4.5 million)

Status

Continued project

Summary

[Project objective]

Objective 1: Conduct a Phase I clinical trial to evaluate the safety and immunogenicity of the LmCen-/- vaccine in healthy volunteers in Brazil (New World)

Objective 2: Conduct a Phase I clinical trial to evaluate the safety and immunogenicity of the LmCen-/- vaccine in healthy volunteers in Kenya (Old World)

[Project design]This project is a continuation of the GHIT-funded project G2018-201 to advance clinical development of the LmCen-/- vaccine. During the previous funding period, the project team successfully accomplished the goals of the project by:

1) Validate the safety and efficacy of a GLP-grade LmCen-/- vaccine produced by Gennova Biopharmaceuticals under cGMP conditions using preclinical animal models,

2) Produce a GMP master cell bank (MCB) and a GMP working cell bank (WCB) of LmCen-/- parasites,

3) Establish cGMP manufacturing of the LmCen-/- vaccine,

4) Complete preclinical toxicology studies in accordance with regulatory guidelines using a GLP LmCen-/- vaccine produced from an engineering run of the cGMP cell bank, and

5) Finalize the IND package for the LmCen-/- product for submission to regulatory authorities.

In the current project, the project team proposes to evaluate the safety of the LmCen-/- vaccine in healthy volunteers living in leishmaniasis-endemic countries, Brazil and Kenya, where other factors such as subclinical nutritional deficiencies and co-infections, such as diarrhea, malaria, Chagas disease (in Brazil) and helminth infections, are common and have been documented to impact vaccine safety and immunogenicity.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/247/en 

ID: G2025-101

Project Title

Strongyloides stercoralis Rapid Test Plus (SsRT+): A new rapid diagnostic test with improved ease of use to support WHO strongyloidiasis control programs.

Collaboration

Partners

1. Drugs & Diagnostics for Tropical Diseases (DDTD) (USA)

2. Medical & Biological Laboratories Co., Ltd. (MBL) (Japan)

3. IRCCS Sacro Cuore Don Calabria Hospital (Italy)

4. QIMR Berghofer Medical Research Institute (Australia)

5. Fundacion Mundo Sano (Spain)

6. Big Eye Diagnostics, Inc. (BEDx) (USA)

Disease

Strongyloidiasis (Soil-transmitted helminth)

Intervention

Diagnostic

Stage

Product Design

Awarded Amount

JPY 566,596,199 (USD 3.8 million)

Status

New

Summary

[Project objective]

The overarching goal of this project is to deliver an easy-to-use, low-cost point-of-care test to detect S. stercoralis infection. Our new test, termed S. stercoralis Rapid Test Plus (SsRT+), will be an improved version of SsRapid, which was developed and validated by our Consultant, Prof. R. Noordin, and has been shown to be 80-97% sensitive and 90-100% specific in a series of laboratory and field studies. A first SsRT+ prototype has already been generated, which showed diagnostic performance comparable to, or better than, SsRapid. SsRT+ will be fully optimized in this project to meet all key criteria of the new TPP for S. stercoralis diagnostics.

[Project design]Objective-1: This first activity aims to review the optimal use case(s) and define the key experimental data to be generated with SsRT+ to align with the WHO strongyloidiasis control programs. We will also finalize the study plans for the field evaluations in Australia and Argentina and complete a business/commercialization plan.

Objective-2: Having access to high-quality antigens and positive control antibodies is key for efficient test development, optimization, and manufacturing under ISO-13485:2016 standards. As for all our other GHIT Fund projects, MBL will be entrusted with the production of high-quality recombinant NIE and IgG4-anti-NIE. 

Objective-3: The SsRT+ prototype available at the outset of G2025-101 will be fully optimized, according to all key criteria listed in the TPP for S. stercoralis diagnostics, including sensitivity, specificity, time to result, result stability, reproducibility (CV values), and cost. Since the precursor of SsRT+, SsRapid, already meets most of the TPP criteria, we consider this a very realistic objective.

Objective-4: Prof. R. Noordin of Universiti Kebangsaan Malaysia (UKM), who has developed and validated SsRapid in numerous laboratory and field studies, and Prof. D. Buonfrate of IRCCS Sacro Cuore Don Calabria Hospital, who has previously run an in-depth diagnostic accuracy study involving SsRapid, will independently evaluate the diagnostic performance of SsRT+ to demonstrate that it complies with the TPP and is not inferior to SsRapid.

Objective-5: Once validated for TPP-compliant performance in the laboratory, SsRT+ will be evaluated in two field studies in Australia and Argentina, conducted by the groups of Prof. D. Gray of QIMR Berghofer and Prof. A. Krolewiecki of Mundo Sano, respectively.

Objective-6: An ISO-13485:2016 compliant automated manufacturing process commensurate with the anticipated demand will be developed by DDTD, modeled on the one we successfully put in place for our Onchocerciasis rapid test in the GHIT Fund project G2023-111, and subsequently validated by BEDx through production of several pilot lots and quantification of inter-lot consistency.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/248/en 

ID: T2024-276

Project Title

Development of Ultrasensitive and Robust Malaria Rapid Diagnostic Tests Using de novo Designed Antigen Binders

Collaboration

Partners

1. Ehime University (Japan)

2. Institute of Tropical Medicine (NEKKEN) Nagasaki University (Japan)

3. Universiti Malaysia Sabah (Malaysia)

Disease

Malaria

Intervention

Diagnostics

Stage

Concept Development

Awarded Amount

JPY 99,670,808 (USD 0.6 million)

Status

New

Summary

[Project objective]

Current malaria Lateral Flow Assays (LFAs) use antibodies as their capture and detection reagents. The limited sensitivity of LFAs in part reflects the relativity modest affinities of typical antibodies for their target proteins. In addition, the identification of antibodies that target related proteins with high specificity is time-consuming and uncertain of success. A technology that replaces monoclonal antibodies could thus have a transformative impact on the development of new diagnostics. We propose to develop novel protein-based affinity reagents that enable the creation of rapid diagnostic tests (RDTs) that diagnose infection with Plasmodium falciparum, non-falciparum malaria parasites, and the emerging pathogen Plasmodium knowlesi with sensitivities that considerably exceed existing alternatives. Our work will result in affinity reagents that integrate directly into the existing infrastructure for the creation of LFAs, the technology used in rapid COVID tests. The products of this project can thus be rapidly scaled to impact malaria treatment worldwide. As part of this project, we will validate our approach using clinical samples. If successful, the diagnostics resulting from our collaboration will possess enhanced sensitivity, greater shelf stability, lower cost, and the elimination of test failure due to parasite mutations, four improvements that have been identified as critically important by the World Health Organization (WHO) for the management of malaria. Success in this project will establish a general-purpose platform for the rapid development of highly sensitive diagnostic assays. In addition to its impact on malaria diagnosis and treatment, this project will thus provide proof-of-concept for a novel platform technology enabling the development of rapidly scalable diagnostics for novel infectious diseases. Our overall goals are thus to develop new protein-based affinity reagents that can improve the sensitivity of malaria LFAs, and to extend malaria LFAs to include diagnosis of infection with P. knowlesi.

[Project design]Our overall strategy is to replace the antibodies that are used in conventional LFAs with computationally designed binders based on the monobody scaffold. The nanomolar (nM) affinities of most antibodies limit the sensitivity of LFAs. To circumvent this limitation, we will use de novo protein design to identify numerous monobody binders for a target malaria antigen of interest. We will then link monobodies together to generate bivalent binders for the malaria antigens. This strategy makes use of the well-known principle of avidity, in which linear improvements in binding energy yield exponential improvements in dissociation constants: both empirical evidence and simple calculations indicate that combining monobody binders with 10-100 nM KD values should yield multivalent binders with KD values in the pM regime. Importantly, this strategy is made possible by the unique ability of computational design to deliberately target multiple, distinct sites on the target protein. We will quantify the binding affinities and cross-reactivity of bivalent monobodies and confirm that they possess the properties required for use in an LFA. Finally, we will assess the performance of the resulting capture and detection reagents in prototype LFAs.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/249/en 

*All amounts are listed at an exchange rate of USD1 = JPY148.81, the approximate exchange rate on September 30, 2025.

Appendix 2. Investment Overview (as of September 30, 2025)

Investments to date
Total investments: 41.0 billion yen (USD 275 million1)
Total invested projects: 141 (42 active projects and 99 completed projects)

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en 

For more information, contact:
Nancy Moss at +1-908-606-8940 or nmoss@burness.com
Mina Ohata at +81-36441-2032 or mina.ohata@ghitfund.org 

Forrester’s 2026 Asia Pacific Predictions: Quantum Security Will Become A Strategic Priority For Over 90% Of Enterprises

By
Advertorial Desk
-

SINGAPORE, Oct. 28, 2025 /PRNewswire/ — According to Forrester’s (Nasdaq: FORR) 2026 Asia Pacific predictions, released today, quantum security will emerge as a top priority for enterprises across the region. More than 90% of Asia Pacific (APAC) firms are expected to invest in post-quantum technologies as cyber threats intensify “harvest now, decrypt later” tactics. Government-led initiatives such as Singapore’s National Quantum-Safe Network Plus and India’s National Quantum Mission will further fuel investments in quantum security, with a strong focus on migration planning and cryptographic inventory solutions.

In 2026, economic, cultural, and regulatory differences across the region will inform technology strategies that emphasize resilience, utility, and cost-effectiveness over hype. Key highlights from Forrester’s 2026 Asia Pacific predictions include:

  • Sovereignty will shape AI infrastructure choices for half of firms. The rise of “diverse cloud” strategies across the Association of Southeast Asian Nations, blending US hyperscalers, Chinese cloud giants, and domestic providers, will be a pragmatic approach to managing geopolitical uncertainty and safeguarding national sovereignty over foundational infrastructure.
  • One-third of firms will waste resources on performative IT product shifts. To meet AI aspirations, many APAC organizations will rebrand delivery teams as product teams without true cultural and operational transformation, resulting in inefficiencies and missed outcomes.
  • The EV boom will drive Chinese hyperscalers to double their growth in APAC. As Chinese electric vehicles dominate regional markets, APAC enterprises are expected to mimic consumer trends of prioritizing utility, price, and innovation, expanding their adoption of Chinese technology platforms.

“In 2026, leaders in the Asia Pacific region will need to recalibrate their tech strategies to factor in local realities while staying globally competitive,” said Dane Anderson, SVP of international research and product at Forrester. “From managing sovereignty concerns and addressing quantum threats to operating in a rapidly evolving cloud landscape, regional business and technology leaders are shifting from proving the value of digital transformation to amplifying its ROI. Our insights are designed to guide leaders in making grounded, high-impact decisions that deliver resilience, utility, and long-term growth.”

Forrester’s annual predictions offer forward-looking insights into trends and signals that empower leaders and their teams to think beyond the conventional and ignite bold ideas in the year ahead. The 2026 technology and security predictions cover topics including artificial intelligence; automation and robotics; tech leadership; cloud computing; tech infrastructure and operations; enterprise software; software development; cybersecurity and risk; and smart manufacturing and mobility.

Resources:

About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.

Tencent’s CarbonX Program 2.0 Identifies 50 Global Finalists in Race to Scale Climate Solutions

By
Advertorial Desk
-

SHENZHEN, China, Oct. 29, 2025 /PRNewswire/ — Tencent (0700.HK) today announced the top 50 finalists, coming from 12 countries and regions around the world, for its CarbonX Program 2.0 (CarbonX 2.0), a landmark initiative to accelerate next generation climate technologies and the essential capabilities needed for a net-zero world by 2050.

These innovators, selected from more than 660 applicants across 54 countries and regions, are competing for a share of RMB200 million (approximately US$28 million) in catalytic funding. Winners will also receive technical resources, expert mentorship, and opportunities to pilot their solutions in real-world environments, including in climate vulnerable regions such as Kenya, the Maldives, and Serbia.

Bridging the “Valley of Death” in Climate Innovation

The path from breakthrough discovery to real-world impact is often blocked by what experts call the ‘Valley of Death’ – the critical gap between early-stage innovation and large-scale deployment. Many climate technologies fail to progress due to limited funding, partnerships, and testing environments.

The CarbonX Program was created to close this gap. It does this by building a global ecosystem where scientists, engineers, entrepreneurs, investors, and industry leaders work together to accelerate the scaling of climate solutions, offering comprehensive support beyond mere financing.

“The climate crisis is the defining challenge of our time and tackling it demands both bold innovation and collective action across the global ecosystem,” said Davis Lin, Senior Vice President of Tencent. “With CarbonX, we are not only investing in groundbreaking ideas, but also creating the pathways to turn them into real-world solutions. By bridging the gap between research and deployment, we aim to accelerate technologies that can store, transform, and reduce CO₂ emissions at scale, laying the foundation for a truly low-carbon future.”

Scaling Climate Innovation Across Borders

Building on the success of its inaugural program focused on China, CarbonX 2.0 has expanded globally to identify and support promising early-stage climate technologies. The 50 finalists represent a diverse mix of universities, research institutes, and startups working at the forefront of four key areas:

  1. Carbon Dioxide Removal (CDR): Supporting pilots in Kenya to accelerate scalable, cost-effective solutions for permanently removing historic CO₂ emissions, with the potential to reduce direct air capture (DAC) costs substantially. 
  2. Industrial Decarbonization (CCUS for Steel): Advancing breakthrough approaches to reduce lifecycle emissions in steel production with pilots in Serbia. The focus is on developing cost-effective and scalable industrial carbon capture, utilization, and storage (CCUS) solutions for hard-to-abate industries.
  3. Carbon Capture and Utilization (CarbonXmade): Transforming captured carbon into chemicals, and ultimately into consumer products. This creates a circular value chain that turns waste into consumer goods, with early market adoption supported by brand premiums in China.
  4. Long-Duration Energy Storage (LDES): Providing real-world scenarios in the Maldives to refine and validate emerging technologies, to meet the growing demands of renewable energy expansion – with flow batteries showing strong promise for commercially viable, long-duration storage.

In early 2026, a global panel of multi-disciplinary experts will evaluate and select the winning teams to receive grants and other resources to pilot their technologies in those regions and create measurable impact.

CarbonX Summit 2025: Inspiring Collective Action

The announcement was made at the CarbonX Summit 2025 in Shenzhen, a convening of finalist teams and leaders from business, academia, and policy to explore how innovation ecosystems can accelerate climate action globally. The Summit spotlighted the role of catalytic finance, inclusive deployment, and multilateral collaboration in achieving the Paris Agreement targets.

“Sustainability can only be achieved through innovation,” said Hao Xu, Head of Climate Innovation at Tencent. “By supporting the world’s brightest climate entrepreneurs, we aim to harness technology as a force for good — addressing one of humanity’s most urgent challenges while creating shared value for future generations.”

For more information about CarbonX 2.0, please visit the program website.

Appendix: List of Top 50 Finalists of CarbonX Program 2.0 https://static.www.tencent.com/attachments/ssv/2025/CarbonX%202.0%20Finalists.pdf 
For media queries, please contact: gc@tencent.com

VUNO Partners with European Firms to Advance DeepCARS® Market Entry in Europe

By
Advertorial Desk
-

– Strategic MOU enhances market access and extends reach to over 900 hospitals across the region

SEOUL, South Korea, Oct. 29, 2025 /PRNewswire/ — VUNO Inc., a global medical AI company, announced today that it has signed a strategic Memorandum of Understanding (MOU) with Contextflow, an Austrian imaging AI company, and Mesalvo, a German hospital information system (HIS) provider, to jointly advance into the European market with its AI-based cardiac arrest prediction solution, VUNO Med®–DeepCARS®.

The MOU was signed on October 27 during a local meeting held in conjunction with the 38th Annual Congress of the European Society of Intensive Care Medicine (ESICM LIVES 2025), which took place from October 25 to 29 in Munich, Germany. Through this agreement, the three companies will collaborate on technical integration, real-world validation, and reimbursement strategies to support the adoption of DeepCARS across European hospitals.

Under the MOU, Contextflow will leverage its expertise in reimbursement and regulatory processes for imaging AI solutions in Europe to support DeepCARS’ regulatory compliance and market access strategy.

Meanwhile, Mesalvo, a major provider of hospital information systems across Europe including Germany, will work on integrating DeepCARS into its electronic health record (EHR) systems and data platforms. Building on the technological integration with Mesalvo’s EHR platform, this partnership positions VUNO’s DeepCARS to potentially reach over 900 hospitals across Europe.

Alongside the MOU signing, VUNO showcased DeepCARS at a dedicated booth at ESICM 2025. Under the slogan “Predict Early, Prevent More,” the company highlighted the solution’s unique features, real-world clinical cases, and superior predictive performance compared to conventional early warning systems. These efforts drew significant interest from intensive care experts across Europe.

Dr. Ye Ha Lee, Founder & CEO of VUNO, commented, “This strategic MOU with Contextflow and Mesalvo marks a significant step toward DeepCARS’ expansion into Europe. By working closely with trusted local partners, we aim to set a new global standard in AI-based patient care that European hospitals and medical professionals can rely on.” 

About VUNO

VUNO, founded in 2014, is a leading South Korean medical AI company and the developer of the nation’s first approved AI-powered medical device. Leveraging cutting-edge AI technology, VUNO analyzes a wide range of medical data—from bio signals such as ECG, respiratory rate and blood pressure to medical images including X-rays, CT scans, and fundus images—to predict critical events and support clinicians in decision-making. Committed to patient-centered innovation, VUNO strives to make high-quality healthcare accessible to everyone, worldwide.

About VUNO Med®-DeepCARS®

VUNO Med®-DeepCARS®(DeepCARS) is an AI-powered medical device designed to monitor the risk of in-hospital cardiac arrest within the next 24 hours. It analyzes patients’ vital signs-including blood pressure, heart rate, respiratory rate, and body temperature-in general wards.

As of September 2025, DeepCARS has been implemented across more than 50,000 hospital beds in South Korea, including over 20 tertiary general hospitals, establishing itself as an essential part of care. In 2023, DeepCARS received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently undergoing the FDA approval process.

 

Wondershare Showcases AI Creative Software Innovations at INTI 2025, Empowering Indonesia’s Digital and Creative Ecosystem

By
Advertorial Desk
-

JAKARTA, Indonesia, Oct. 28, 2025 /PRNewswire/ — Wondershare, a global leader in creative and productivity software, drew strong attention at Indonesia Technology & Innovation (INTI) 2025 with its comprehensive lineup of AI-powered creative solutions. Under the theme “More AI, More Efficiency,” Wondershare showcased its flagship products — ToMoviee AI, Filmora, PDFelement, EdrawMax, and Dr.Fone — demonstrated how artificial intelligence is transforming the way individuals and organizations create, collaborate, and innovate across industries—particularly within Indonesia’s fast-growing creative economy.

Wondershare, a global leader in creative and productivity software, drew strong attention at INTI 2025 with its comprehensive lineup of AI-powered creative solutions.
Wondershare, a global leader in creative and productivity software, drew strong attention at INTI 2025 with its comprehensive lineup of AI-powered creative solutions.

As one of Southeast Asia’s fastest-growing digital economies, Indonesia is advancing its vision to become a “Digital Nation” by 2035. AI technologies are central to this transformation, driving new opportunities for creators, educators, and businesses alike. Against this backdrop, Wondershare’s participation at INTI 2025 reflects its commitment to supporting Indonesia’s digital and creative economy—helping creators, educators, and enterprises harness AI to turn ideas into impact.

AI-Powered Creativity in Action

At INTI, Wondershare’s booth attracted a steady flow of visitors eager to explore the future of AI-powered creation. ToMoviee AI captivated creators with its all-in-one creative workflow — enabling users to generate videos, images, and soundtracks from text prompts and customize them with AI-driven camera movements, lighting effects, and cinematic styles. Wondershare Filmora further showcased how AI-assisted editing, auto scriptwriting, and voice synthesis simplify complex production tasks, empowering content creators to turn ideas into polished videos with greater speed, precision, and creativity.

For professionals and enterprises, Wondershare demonstrated how AI is redefining digital productivity and collaboration. Wondershare EdrawMax impressed attendees with its AI Diagram Generator, which instantly converts text descriptions into professional flowcharts, organizational charts, and business diagrams, making complex ideas easy to visualize and share. Meanwhile, Wondershare PDFelement showcased its AI Smart Form Recognition and AI Summary & Proofreading features, which streamline document management and accelerate team collaboration — helping businesses transition toward smarter, more efficient digital workflows.

Empowering Indonesia’s Creative Ecosystem

“Indonesia’s creative economy is entering an exciting new phase, where AI is becoming the driving force behind innovation and growth.” said Rocky, Global Head of Government and Enterprise Business at Wondershare. “By participating in INTI 2025, we’re deepening our collaboration with local partners to accelerate digital transformation and empower creators and organizations with AI tools that enhance creativity and productivity.”

Wondershare’s AI-powered solutions have already been widely adopted across industries such as energy, finance, logistics, IT, aerospace, and education. In Indonesia, Wondershare sees growing demand from creative professionals, educators, and small businesses seeking to integrate AI into their workflows to boost efficiency and content quality.

Building on its expanding global footprint, Wondershare has actively showcased its AI innovations at major international technology events, including GITEX GLOBAL 2025 (UAE), GITEX Europe (Berlin), LEAP 2025 (Riyadh), EDIX Tokyo, MWC 2025 (Barcelona), and more. By extending these innovations to Southeast Asia, Wondershare aims to connect Indonesia’s vibrant creative community to a global network of AI-driven creators and innovators.

About Wondershare:

Wondershare  is a globally recognized software company founded in 2003, known for its innovative solutions in creativity and productivity. Driven by the mission “Creativity Simplified”, Wondershare offers a range of tools, including ToMoviee AI, Filmora and SelfyzAI for video editing; PDFelement for document management; and EdrawMax, EdrawMind for diagramming. With over 2 billion cumulative active users across all products and a presence in over 200 countries and regions, Wondershare empowers the next generation of creators with intuitive software and trendy creative resources, continually expanding the possibilities of creativity worldwide.

A Signal Through the Mountains: Zhejiang Mobile’s 5G Brings Care to Rural China

By
Advertorial Desk
-

LISHUI, CHINA – Media OutReach Newswire – 29 October 2025 – At the 78th World Health Assembly in Geneva earlier this year, a rural healthcare project from eastern China drew global attention.

image-1.jpeg

The mountain county of Jingning She Autonomous County in Zhejiang’s Lishui City introduced its “Smart Mobile Hospital + AI” model — an innovation that shows how digital transformation can bring quality medical services to remote regions.

Delegates said the project offers a glimpse into how technology can bridge healthcare gaps for mountain communities, where access to doctors has long been limited by geography.

For 81‑year‑old Liu Yuyu, those gaps used to mean several hours on steep mountain roads just to see a specialist in Hangzhou, the provincial capital. Now she simply visits her township clinic and meets doctors through a high‑definition screen. Her entire medical history, stored in Zhejiang’s cloud‑based health system, allows specialists hundreds of kilometers away to review her data and adjust treatment in real time.

Such changes are reshaping healthcare in Jingning She Autonomous County in Lishui City, Liu’s mountainous hometown in eastern Zhejiang. Powered by Zhejiang Mobile’s 5G network, artificial intelligence and big‑data tools, the “Smart Mobile Hospital + AI” program is bringing advanced care to even the most remote villages.

In Jingning, known as a land of “nine parts mountain, half part water and half part field,” visiting a doctor has long been a challenge. Some residents still spend an hour to reach a township clinic and more than two hours to the county hospital. With the new system, consultations and diagnostics once requiring a trip to the city can now happen almost instantly.

To overcome the region’s rugged geography, Zhejiang Mobile has transformed its service vehicles into 5G‑enabled mobile clinics. Each van maintains a stable signal on winding roads, transmitting high‑resolution images and test results to upper‑level hospitals. Inside, AI‑based software analyzes symptoms and supports local doctors in diagnosing patients and recommending treatments.

Each vehicle works as a mini hospital, equipped with more than 20 types of medical devices — from portable ultrasounds and ECG monitors to lung‑function analyzers. Township physicians can perform examinations, prescribe medication, and even provide emergency care on site. For complicated cases, they connect instantly with specialists in city or provincial hospitals through the same 5G network.

Inside the Zhejiang Mobile 5G‑enabled mobile clinic, a doctor is using connected diagnostic devices to examine patients and transmit real‑time data to upper‑level hospitals.
Inside the Zhejiang Mobile 5G‑enabled mobile clinic, a doctor is using connected diagnostic devices to examine patients and transmit real‑time data to upper‑level hospitals.

Local health authorities say Zhejiang Mobile’s platform helps automate the screening of chronic illnesses such as hypertension, coronary heart disease and cataracts, recommending drugs or further tests. This has significantly improved early detection and reduced serious cases among elderly residents.

To make the “Smart Mobile Hospital” serve not only daily clinical needs but also emergency response, Zhejiang Mobile worked with local authorities to connect data systems across public security, civil affairs and social‑insurance departments. The company helped build an integrated workflow that unites pre‑hospital emergency services with in‑hospital treatment.

When an emergency occurs in a remote mountain area, the system can automatically match and dispatch both a mobile hospital and an ambulance, ensuring rapid, coordinated rescue.

“When patients board the vehicle, facial‑recognition technology immediately confirms their identity and retrieves family and insurance information,” said Chen Lifeng, the director of the Dajun Township Health Center in Jingning County. “All registration and admission procedures are completed in advance, so the patient is effectively admitted upon boarding.”

Through a real‑time 5G link between the vehicle and the hospital, vital‑sign data is transmitted to emergency rooms as doctors provide remote guidance. This enables continuous treatment across the chain — from rescue site to vehicle to hospital.

Seven Zhejiang Mobile medical units now serve Jingning County, covering 67 villages and 78 regular stops. They have traveled more than 250,000 kilometers and delivered care to over 100,000 residents. For families once separated from modern healthcare by mountains, access is finally within reach.

Local doctors say 5G and AI are changing not only how patients are treated but how they think about medicine. Regular screenings catch illnesses earlier, and growing trust in remote consultations encourages people to seek help sooner.

As China continues modernizing its vast primary‑healthcare network, Jingning’s experiment is being closely watched. Zhejiang Mobile’s Smart Mobile Hospital may become a model for other remote regions seeking affordable, technology‑driven medical solutions.

Liu, who once dreaded the long trip to the city, now jokes that her doctors travel farther than she does. “They come here through the screen,” she says with a laugh. “And I don’t miss the bus anymore.”

Hashtag: #ChinaMobileCommunicationsGroupZhejiang

The issuer is solely responsible for the content of this announcement.

Appian is Named a Leader in Inaugural Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT)

By
Advertorial Desk
-

MCLEAN, Va., Oct. 29, 2025 /PRNewswire/ — Appian (Nasdaq: APPN), the leading platform for AI process automation, today announced that it has been named a Leader in the 2025 Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT).

Appian is Named a Leader in Inaugural Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT)
Appian is Named a Leader in Inaugural Gartner® Magic Quadrant™ for Business Orchestration and Automation Technologies (BOAT)

In our opinion, this new market signals a shift toward more unified enterprise automation. Organizations are moving away from separate vendors for LCAP, RPA, BPA, and iPaaS in favor of a single platform with native capabilities for each.

According to Gartner, “Business orchestration and automation technology platforms unify process orchestration, connectivity and agentic features to enable enterprisewide automation.”

BOAT platforms are designed to help organizations orchestrate complex workflows across systems, data, and people, eliminating silos and driving measurable business impact. Appian believes this Leader recognition validates its vision for end-to-end process orchestration powered by data and AI.

“By deploying powerful AI agents within processes, organizations can orchestrate data, AI, and processes in a single enterprise-grade platform. This approach combines the structure of processes with the flexibility of AI agents, delivering higher levels of automation,” said Sanat Joshi, Executive Vice President, Product and Solutions at Appian.

Appian was recognized by Gartner as a comprehensive BOAT platform. With AI agents that embed directly into existing business processes, we believe organizations can use Appian to automate more complex, multi-step work. And with Appian’s unified data fabric to connect data across sources, organizations get real-time observability and measurable results at scale.

View a complimentary copy of the report and learn more about the Gartner evaluation https://ap.pn/4o5wKXD.

About Appian

Appian is The Process Company. We deliver a software platform that helps organizations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across various industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

Gartner, Magic Quadrant for Business Orchestration and Automation Technologies, 24 October 2025, Siakat Ray, Art Villa, et al.

Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved. This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Appian.

 

Photo – https://laotiantimes.com/wp-content/uploads/2025/10/appian_gartner_boat_award.jpg 
Logo – https://laotiantimes.com/wp-content/uploads/2025/10/appian_caption_2700px_logo-2.jpg

1...2,0282,0292,030...6,508Page 2,029 of 6,508